Federal Register / Vol. 70, No. 223 / Monday, November 21, 2005 / Notices 70079 

FEE SCHEDULE JANUARY 1, 2006–SEPTEMBER 30, 2006 

Vessel size GRT 1 Fee 

Extra Small .................................................................................................................................................. <3,001 1,300 

Small ............................................................................................................................................................ 3,001–15,000 2,600 

Medium ........................................................................................................................................................ 15,001–30,000 5,200 

Large ............................................................................................................................................................ 30,001–60,000 7,800 

Extra Large .................................................................................................................................................. >60,000 10,400 

1Gross register tonnage in cubic feet, as shown in Lloyd’s Register of Shipping. 

Inspections and reinspections involve the 

same procedure, require the same amount of 

time, and are therefore charged at the same 

rate. 

[FR Doc. 05–22967 Filed 11–18–05; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Notice of Approval of Supplemental 

New Animal Drug Application; 

Ivermectin and Praziquantel Paste 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is providing 

notice that it has approved a 

supplemental new animal drug 

application (NADA) filed by Merial, Ltd. 

The NADA provides for oral use of an 

ivermectin and praziquantel paste as an 

over-the-counter product for the 

treatment and control of various 

parasitic conditions of horses. This 

supplemental NADA reduces the 

minimum age for administration from 5 

months to 2 months of age. 

FOR FURTHER INFORMATION CONTACT: 

Melanie R. Berson, Center for Veterinary 

Medicine (HFV–110), Food and Drug 

Administration, 7500 Standish Pl., 

Rockville, MD 20855, 301–827–7543, email: melanie.berson@fda.gov. 

SUPPLEMENTARY INFORMATION: Merial, 

Ltd., 3239 Satellite Blvd., bldg. 500, 

Duluth, GA 30096–4640, filed a 

supplement to NADA 141–214 for 

ZIMECTERIN GOLD (ivermectin 1.55%/ 

praziquantel 7.75%) Paste, an over-thecounter product used for the oral 

treatment and control of various 

parasitic conditions of horses. This 

supplemental NADA reduces the 

minimum age for administration from 5 

months to 2 months of age. In 

accordance with section 512(i) of the 

Federal Food, Drug, and Cosmetic Act 

(the act) (21 U.S.C. 360b(i)) and part 514 

(21 CFR part 514) in §§ 514.105(a) and 

514.106(a), the Center for Veterinary 

Medicine is providing notice that this 

supplemental NADA is approved as of 

October 28, 2005. The basis of approval 

is discussed in the freedom of 

information summary. 

In accordance with the freedom of 

information provisions of 21 CFR part 

20 and § 514.11(e)(2)(ii), a summary of 

safety and effectiveness data and 

information submitted to support 

approval of this application may be seen 

in the Division of Dockets Management 

(HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD 20852, between 9 

a.m. and 4 p.m., Monday through 

Friday. 

FDA has determined under 21 CFR 

25.33(d)(1) that this action is of a type 

that does not individually or 

cumulatively have a significant effect on 

the human environment. Therefore, 

neither an environmental assessment 

nor an environmental impact statement 

is required. 

Dated: November 7, 2005. 

Steven D. Vaughn, 

Director, Office of New Animal Drug 

Evaluation, Center for Veterinary Medicine. 

[FR Doc. 05–22941 Filed 11–18–05; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Eye Institute; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Eye Institute 

Special Emphasis Panel, Gene Therapy 

Clinical Trial. 

Date: November 21, 2005. 

Time: 1 p.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Sheraton Gateway Hotel Los Angeles 

Airport, 6101 W Century Blvd., Los Angeles, 

CA 90045. 

Contact Person: Samuel Rawlings, PhD, 

Chief, Scientific Review Branch, Division of 

Extramural Research, National Eye Institute, 

5635 Fishers Lane, Suite 1300, MSC 9300, 

Bethesda, MD 20892–9300, 301–451–2020. 

(Catalogue of Federal Domestic 

Assistance Program No. 93.867, Vision 

Research, National Institutes of Health, 

HHS) 

Dated: November 14, 2005. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 05–22932 Filed 11–18–05; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

Board of Scientific Counselors, NHLBI. 

The meeting will be closed to the 

public as indicated below in accordance 

with the provisions set forth in section 

552b(c)(6), Title 5 U.S.C., as amended 

for the review, discussion, and 

evaluation of individual grant 

applications conducted by the National 

Heart, Lung, and Blood Institute, 

including consideration of personnel 

qualifications and performance, and the 

competence of individual investigators, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Board of Scientific 

Counselors, NHLBI.